The companies have also initiated a phase 1/2/3 study to evaluate different doses and dosing regimens of the BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 11 years of age.
Pfizer and BioNTech are requesting emergency use authorization (EUA) of a 10-µg booster dose of the companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age.
The request in this age group is supported by safety and immunogenicity data from the companies’ bivalent omicron BA.1-adapted vaccine, nonclinical and manufacturing data from the companies’ 10-µg bivalent omicron BA.4/BA.5-adapted vaccine, and preclinical data from the companies’ omicron BA.4/BA.5-adapted vaccine.
An application to extend the omicron BA.4/BA.5-adapted bivalent vaccine marketing authorization to include children ages 5 through 11 years will be submitted to the European Medicines Agency (EMA) in the coming days.
The companies have also initiated a phase 1/2/3 study to evaluate the safety, tolerability, and immunogenicity of different doses and dosing regimens of the companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 11 years of age. The study will have four substudies examining different dosing regimens and ages. This includes:
In August 2022, the FDA amended the emergency use authorizations of both the updated Moderna and the Pfizer/BioNTech COVID-19 booster vaccines that include the omicron variants. The updated boosters are bivalent vaccines and contain two messenger RNA (mRNA) components, one of the original strain of the SARS-CoV-2 and the BA.1, BA.4 and BA.5 omicron variant.